Highlights
- The a2 Milk Company (ASX:A2M) estimated China-label formula offtake at around half of pre-disruption levels.
- China-label offtake improved from approximately 40% of earlier levels in August 2026.
- FY27 Revenue growth is expected in the mid-single digits, with an underlying EBITDA Margin near 15%.
- The company expects FY27 revenue and EBITDA to be materially weighted towards the second half.
The a2 Milk Company (ASX:A2M) supplies branded infant milk formula, nutritional products and liquid milk, with China an important market for its infant nutrition business. At its November 2026 annual meeting, the group outlined progress following Supply disruptions that affected formula availability and described the spending, product changes and distribution measures supporting its FY27 recovery plan.
China-Label Formula Availability and Customer Recovery
The company reported that estimated China-label infant milk formula offtake had recovered to approximately 50% of levels before the supply disruption, compared with around 40% in August 2026.
Supply shortfalls during the fourth quarter of FY26 restricted product availability and prompted many existing users to switch to alternative brands. The company previously identified production backlogs, freight challenges, extended product-release times and customs requirements among the contributing factors. Restoring availability, however, does not necessarily mean previous customers will immediately return.
Product Launches and Marketing Investment
Management expects gradual recovery in both China-label and English-label formula sales during FY27. The plan includes two recently launched China-label products, an updated a2 Platinum range and steps to address China importation requirements affecting a2 Genesis.
Marketing expenditure is expected to increase, particularly in the first half, to support customer recruitment and recovery. The group also anticipates approximately NZD 15 million in FY27 one-off transformation costs, including costs associated with transferring a2 Platinum production to its Pōkeno facility. That transition was described as on track; the company does not expect further transformation costs in FY28.
FY27 Revenue, Margins and Earnings Timing
The November outlook retained an expectation of mid-single-digit percentage revenue growth for FY27 on a continuing-operations basis. First-half revenue is expected to be slightly below the comparable FY26 period. Management expects an underlying EBITDA margin of approximately 15% for the full year, with the first-half margin materially below the prior corresponding period. Revenue and EBITDA are therefore expected to be materially weighted towards the second half.
The group expects total infant milk formula sales to be broadly similar to FY26, while product innovation, new markets, Other Nutritionals, Liquid Milk and improvements at the Pōkeno site provide other potential contributions. The outlook also anticipates Capital Expenditure of approximately NZD 70 million and cash conversion of approximately 70%–80%.
What Could Affect the Recovery?
The rate at which China-label Demand returns remains a central uncertainty. The company identified competitive intensity, product and supply risks, Import and export requirements, currency movements and geopolitical developments among factors that could alter outcomes. It also noted that New Zealand dollar Depreciation could lift reported revenue and expenses, while associated earnings benefits would be offset by hedge losses. Subsequent updates will be needed to assess whether sales recovery and second-half earnings weighting materialise.
Key Insights
The November update shows partial recovery in China-label formula offtake alongside greater marketing Investment and product changes. FY27 guidance anticipates stronger second-half activity, but customer recruitment, importation requirements and operating costs remain important variables.



_11_20_2026_05_24_47_863166.jpg)


Please wait processing your request...